136 related articles for article (PubMed ID: 24258983)
1. Immunohistochemical diagnostic and prognostic markers for melanoma.
Nosrati M; Kashani-Sabet M
Methods Mol Biol; 2014; 1102():259-73. PubMed ID: 24258983
[TBL] [Abstract][Full Text] [Related]
2. Skin layer-specific Melan-A expression during progression of human cutaneous melanoma: implications for diagnostic applications of the marker.
Sztramska A; Dymerska D; Chwirot BW
Melanoma Res; 2008 Aug; 18(4):259-67. PubMed ID: 18626310
[TBL] [Abstract][Full Text] [Related]
3. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
4. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
5. Systematic search for the best gene expression markers for melanoma micrometastasis detection.
Soikkeli J; Lukk M; Nummela P; Virolainen S; Jahkola T; Katainen R; Harju L; Ukkonen E; Saksela O; Hölttä E
J Pathol; 2007 Oct; 213(2):180-9. PubMed ID: 17891747
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
7. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma.
Mason A; Wititsuwannakul J; Klump VR; Lott J; Lazova R
J Cutan Pathol; 2012 Dec; 39(12):1062-74. PubMed ID: 23005921
[TBL] [Abstract][Full Text] [Related]
8. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
Gleason BC; Nascimento AF
Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
[TBL] [Abstract][Full Text] [Related]
9. Accurate identification of proliferative index in melanocytic neoplasms with Melan-A/Ki-67 double stain.
Puri PK; Valdes CL; Burchette JL; Grichnik JM; Turner JW; Selim MA
J Cutan Pathol; 2010 Sep; 37(9):1010-2. PubMed ID: 20002650
[No Abstract] [Full Text] [Related]
10. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Meyer S; Wild PJ; Vogt T; Bataille F; Ehret C; Gantner S; Landthaler M; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
Exp Dermatol; 2010 Aug; 19(8):e251-7. PubMed ID: 20500769
[TBL] [Abstract][Full Text] [Related]
11. Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
Perry BN; Cohen C; Govindarajan B; Cotsonis G; Arbiser JL
Arch Dermatol; 2006 Aug; 142(8):1031-4. PubMed ID: 16924053
[TBL] [Abstract][Full Text] [Related]
12. Melanoma or not? Cancer testis antigens may help.
Lüftl M; Schuler G; Jungbluth AA
Br J Dermatol; 2004 Dec; 151(6):1213-8. PubMed ID: 15606517
[TBL] [Abstract][Full Text] [Related]
13. [Malignant melanoma: conceptual and therapeutic innovations based on translational research].
Piérard GE; Quatresooz P; Rorive A; Piérard-Franchimont C;
Rev Med Liege; 2008 Oct; 63(10):579-84. PubMed ID: 19009964
[TBL] [Abstract][Full Text] [Related]
14. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis.
King R; Weilbaecher KN; McGill G; Cooley E; Mihm M; Fisher DE
Am J Pathol; 1999 Sep; 155(3):731-8. PubMed ID: 10487831
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions.
Nielsen PS; Riber-Hansen R; Steiniche T
Am J Dermatopathol; 2011 Jun; 33(4):361-70. PubMed ID: 21610457
[TBL] [Abstract][Full Text] [Related]
16. Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens.
Lim E; Browning J; MacGregor D; Davis ID; Cebon JS
Melanoma Res; 2006 Aug; 16(4):347-55. PubMed ID: 16845331
[TBL] [Abstract][Full Text] [Related]
17. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
18. Prognostic tissue markers in melanoma.
Moore DA; Pringle JH; Saldanha GS
Histopathology; 2012 Apr; 60(5):679-89. PubMed ID: 21880059
[TBL] [Abstract][Full Text] [Related]
19. Procollagen 1 and Melan-A expression in desmoplastic melanomas.
Leinweber B; Hofmann-Wellenhof R; Kaddu S; McCalmont TH
Am J Dermatopathol; 2009 Apr; 31(2):173-6. PubMed ID: 19318805
[TBL] [Abstract][Full Text] [Related]
20. Cell adhesion and communication proteins are differentially expressed in melanoma progression model.
Rezze GG; Fregnani JH; Duprat J; Landman G
Hum Pathol; 2011 Mar; 42(3):409-18. PubMed ID: 21193224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
